Q-omics provides the consensus-scored SLC16A12-AS1 profile across patient tissues and cancer cell-line models. SLC16A12-AS1 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC16A12-AS1 is differentially expressed in 6, with the highest sampling consensus in KIRP. Additionally, SLC16A12-AS1 RNA expression shows 9,708 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, KIRP, and PDAC as cancer lineages where SLC16A12-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC16A12-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC16A12-AS1 survival associations across molecular data types. SLC16A12-AS1 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC16A12-AS1 RNA expression–survival associations across cancer types. High SLC16A12-AS1 expression shows unfavorable associations in LUSC and LGG, but favorable associations in KIRC, MESO, KIRP and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC16A12-AS1 RNA expression.
This table summarizes SLC16A12-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for SLC16A12-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC16A12-AS1 shows lower tumor expression in KIRP, KICH, THCA, LUSC and LUAD and higher tumor expression in LIHC. The KIRP box plot shows higher SLC16A12-AS1 RNA expression in normal versus tumor tissue (log2 FC = −1.942, t-test p < 0.001).
This table shows molecular features associated with SLC16A12-AS1 in patient tissues and cancer cell lines. In patient samples, SLC16A12-AS1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
